Abstract:Latest results on the action of adenosine A2A receptor antagonists indicate their potential therapeutic usefulness in the treatment of Parkinson’s disease. Basal ganglia possess high levels of adenosine A2A receptors, mainly on the external surfaces of neurons located at the indirect tracts between the striatum, globus pallidus, and substantia nigra. Experiments with animal models of Parkinson’s disease indicate that adenosine A2A receptors are strongly involved in the regulation of the central nervous system. Co-localization of adenosine A2A and dopaminergic D2 receptors in striatum creates a milieu for antagonistic interaction between adenosine and dopamine. The experimental data prove that the best improvement of mobility in patients with Parkinson’s disease could be achieved with simultaneous activation of dopaminergic D2 receptors and inhibition of adenosine A2A receptors. In animal models of Parkinson’s disease, the use of selective antagonists of adenosine A2A receptors, such as istradefylline, led to the reversibility of movement dysfunction. These compounds might improve mobility during both monotherapy and co-administration with L-DOPA and dopamine receptor agonists. The use of adenosine A2A receptor antagonists in combination therapy enables the reduction of the L-DOPA doses, as well as a reduction of side effects. In combination therapy, the adenosine A2A receptor antagonists might be used in both moderate and advanced stages of Parkinson’s disease. The long-lasting administration of adenosine A2A receptor antagonists does not decrease the patient response and does not cause side effects typical of L-DOPA therapy. It was demonstrated in various animal models that inhibition of adenosine A2A receptors not only decreases the movement disturbance, but also reveals a neuroprotective activity, which might impede or stop the progression of the disease. Recently, clinical trials were completed on the use of istradefylline (KW-6002), an inhibitor of adenosine A2A receptors, as an anti-Parkinson drug.

Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective

Development of Adenosine A 2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge.

An Update on Potential Therapeutic Strategies for Parkinson’s Disease Based on Pathogenic Mechanisms

Impact of the apelin/APJ axis in the pathogenesis of Parkinson's disease with therapeutic potential

Adenosine A2A receptors in Parkinson’s disease treatment

Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets

Metabolomics-driven identification of adenosine deaminase as therapeutic target in a mouse model of Parkinson's disease.

Recent Advances in Dopaminergic Strategies for the Treatment of Parkinson’s Disease

Optimization of 6-Heterocyclic-2-(1h-pyrazol-1-yl)-n-(pyridin-2-yl)pyrimidin-4-amine As Potent Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease.

Signaling Pathways in Parkinson’s Disease: Molecular Mechanisms and Therapeutic Interventions

Parkinson’s disease: etiopathogenesis and treatment

Recent Advances in Discovery and Development of Natural Products As Source for Anti-Parkinson's Disease Lead Compounds

AMPK Signaling Pathway as a Potential Therapeutic Target for Parkinson’s Disease

Kinases and Kinase Signaling Pathways: Potential Therapeutic Targets in Parkinson's Disease

Dopaminergic modulation of striatal function and Parkinson’s disease

Metabolic Mechanisms Connecting Alzheimer's and Parkinson's Diseases: Potential Avenues for Novel Therapeutic Approaches

The role of tyrosine hydroxylase–dopamine pathway in Parkinson's disease pathogenesis

A Comprehensive Approach to Parkinson's Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects

Implications of Successful Symptomatic Treatment in Parkinson’s Disease for Therapeutic Strategies of Alzheimer’s Disease

The autophagy-lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson’s disease

Advances in the anti-Parkinson's disease drugs